Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking males or females aged 18 to 80 who are candidates for sedated endoscopy with treatment of BE.~* At least 3 centimeters segment length of Barrett's Esophagus (BE) with or without circumferential involvement (i.e. CxM3) and with high grade or low grade dysplasia based on pathology results from 4 quadrant biopsies taken every 1-2 centimeter throughout the BE. All readings of dysplasia will be confirmed by an expert pathologist.~* Willing to undergo spray cryotherapy and judged by patient's physician as an appropriate candidate for this therapy.~* Able to read, comprehend, and complete the informed consent form~Exclusion Criteria:~* Bleeding disorder or other contraindication of spray cryotherapy.~* History of partial or complete esophagectomy.~* Current or past diagnosis of invasive esophageal cancer (previous intramucosal cancer is allowable, if removed by endoscopic mucosal resection with histologically confirmed negative lateral and deep margins).~* Pregnant women~* Contraindication to endoscopic spray cryotherapy as outlined in the directions for use for the device~* Previous endoscopic ablation treatment (such as radiofrequency ablation (RFA) or photodynamic therapy (PDT)).~* Previous chest external beam radiation therapy.~* Previous wide-area endoscopic resection or submucosal dissection. Previous focal mucosal resection is permitted (maximum 2 previous EMR's of 2cm or less removed representing less than 25% of the circumference of the esophagus removed).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: ACTIVE_COMPARATOR): The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
- Dose 2 (Type: ACTIVE_COMPARATOR): If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
- Dose 3 (Type: ACTIVE_COMPARATOR): If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
- Dose 4 (Type: ACTIVE_COMPARATOR): If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).